MIRM Stock Forecast & Price Target

Mirum Pharmaceuticals is expected to see a strong market demand for its rare disease treatments, with the potential approval of volixibat for cholestatic pruritis in PSC patients and MRM-3379 for Fragile X syndrome in 2027. The company's solid financials, with a projected net present value of $12.3B and ample cash reserves of $383M, along with a manageable 9.1% treatment-related discontinuation rate for its medicines, makes it an attractive investment opportunity. Additionally, the positive VISTA and AZURE-1 study results for volixibat demonstrate its potential to address a significant unmet need in Alagille syndrome and Primary Sclerosing Cholangitis, further supporting a positive outlook for the company's stock.

Mirum Pharmaceuticals is facing significant risks that could impact their stock price, including (1) potential issues with commercialization of their approved products, (2) potential issues with the clinical trial readouts of their ongoing studies, and (3) potential dilution from future financing needs. Additionally, competition in their target markets and legal and intellectual property concerns also pose potential risks. Analysts have set a 12-month price target of $150 per share based on a risk-adjusted net present value analysis, projecting peak revenues of over $700 million for volixibat and over $675 million for brelovitug. However, these projections may prove conservative and there is potential for delays or underperformance in clinical trials, which could significantly impact the company's financials.